Health Care [ 7/12 ] | Biotechnology [ 39/74 ]
NASDAQ | Common Stock
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally.
The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia.
Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions.
The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 5, 25 | 1.69 Increased by +17.36% | 1.93 Decreased by -12.41% |
| Oct 30, 24 | 1.24 Increased by +51.22% | 1.51 Decreased by -17.88% |
| Aug 1, 24 | 0.63 Decreased by -33.68% | 1.05 Decreased by -40.00% |
| May 1, 24 | 0.42 Increased by +153.16% | 1.01 Decreased by -58.42% |
| Feb 7, 24 | 1.44 Increased by +63.64% | 1.15 Increased by +25.22% |
| Oct 31, 23 | 0.82 Increased by +18.84% | 0.97 Decreased by -15.46% |
| Aug 1, 23 | 0.95 Increased by +627.78% | 0.78 Increased by +21.79% |
| May 3, 23 | -0.79 Decreased by -664.29% | 0.13 Decreased by -707.69% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 627.70 M Increased by +21.84% | 103.10 M Decreased by -30.20% | Increased by +16.43% Decreased by -42.71% |
| Sep 30, 24 | 622.10 M Increased by +24.72% | 129.80 M Increased by +56.20% | Increased by +20.86% Increased by +25.24% |
| Jun 30, 24 | 590.20 M Increased by +30.37% | 65.00 M Decreased by -31.94% | Increased by +11.01% Decreased by -47.79% |
| Mar 31, 24 | 515.30 M Increased by +22.57% | 43.40 M Increased by +156.66% | Increased by +8.42% Increased by +146.22% |
| Dec 31, 23 | 515.20 M Increased by +25.05% | 147.70 M Increased by +65.96% | Increased by +28.67% Increased by +32.71% |
| Sep 30, 23 | 498.80 M Increased by +28.59% | 83.10 M Increased by +21.31% | Increased by +16.66% Decreased by -5.66% |
| Jun 30, 23 | 452.70 M Increased by +19.70% | 95.50 M Increased by +665.09% | Increased by +21.10% Increased by +572.09% |
| Mar 31, 23 | 420.40 M Increased by +35.35% | -76.60 M Decreased by -651.08% | Decreased by -18.22% Decreased by -507.15% |